ALS breakthrough could be worth billions for global health systems

New economic analysis has estimated that the development of an effective treatment for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND), could be worth billions to health systems and economies across several major markets.

Economic impact

The research, conducted by the Office of Health Economics, found that an effective ALS treatment could generate between USD $26 billion and USD $ 40 billion in value over a decade in the United States. In the United Kingdom, the estimated 10-year value would be around USD $1.7 billion. Meanwhile, in Canada, Australia, Italy, Germany, and France, the projected benefits range from USD $1.1 billion to USD $ 4 billion each. If ALS could be eradicated, the total value to health systems across the seven nations over 10 years could amount to USD $143 billion.

ALS is a rare but severe neurodegenerative disorder characterised by progressive nerve damage in the brain and spinal cord. The disease interrupts signals from the brain to muscles, ultimately impairing the ability to swallow, speak, and breathe. Approximately one in 300 people will develop MND during their lifetime, and around 90% of these cases are ALS.

Healthcare burden

Current annual medical spending on ALS in the UK is estimated at USD $178 million (GBP £133 million), and at USD $2.5 billion in the US. Including lost productivity and informal caregiving, the overall annual cost triples. Despite its impact, little progress has been made towards new diagnostics or treatments, and no cure currently exists. Patients typically have a life expectancy of two to five years following diagnosis, and the disease requires intensive health and social care resources.

Research momentum

Recent increases in research investment, advances in disease understanding, access to larger datasets and the application of artificial intelligence to drug discovery have created renewed interest in tackling ALS. The Longitude Prize on ALS, a GBP £7.5 million initiative, aims to support AI-led innovations in identifying and validating new drug targets in order to transform treatment discovery for the disease.

"For too long, ALS has been an area of high risk and low investment, but things are changing. Advances in AI, combined with better understanding of the disease and higher volumes of patient data, mean that we find ourselves at a turning point for uncovering potential new treatment pathways. OHE's research quantifies the significant value this would bring to individuals and societies, and we hope the Longitude Prize on ALS will mark a step towards discovering new treatments, and edge us ever closer to a cure," said Tris Dyson, Managing Director, Challenge Works.

Quality of life

The effects of ALS are also pronounced when considered from the perspective of the patient's quality of life. Quality-adjusted life years (QALYs) lost for an individual diagnosed with ALS in the UK average 12.6 over a lifetime. The disease also imposes substantial strain on families and support networks, in addition to the pressure on hospitals and care services.

"The burden of ALS is particularly stark when expressed in terms of quality-adjusted life years (QALYs) lost. In the UK, an individual diagnosed with ALS may lose (on average) 12.6 QALYs over their lifetime. Furthermore, ALS patients require intensive care, placing huge strain on healthcare systems, as well as families and support networks. The value of an effective treatment would be significant, and lifechanging for those living with the disease," said Dr Amanda Cole, Director, Office of Health Economics.

Industry opportunity

For the pharmaceutical sector, ALS presents what some see as a timely mix of urgent medical need and commercial potential. The rapid progression of ALS can enable shorter clinical trials, and previously approved therapies have seen fast adoption. Orphan disease status can also expedite regulatory processes, and platform trials allow for the simultaneous testing of multiple drugs.

"ALS offers biopharmaceutical companies strategic convergence where urgent unmet need meets compelling commercial opportunity. Investing here makes strategic sense: rapid disease progression enables shorter, more cost-effective trials; approved treatments have seen fast uptake; platform trials allow multiple drugs to be tested efficiently; and orphan status accelerates regulatory approval. Crucially, ALS also acts as a proof-of-concept for technologies that could be applied to other neurodegenerative diseases, unlocking further opportunities. Breakthroughs are urgently needed, and OHE's research makes a strong case for investing in this area," said Dr Vishal Gulati, Founder and Managing Partner, Recode Ventures and Longitude Prize on ALS judge.